Mutual Advisors’s Bionano Genomics BNGO Stock Holding History

Mutual Advisors’s Portfolio BNGO Stock Details BNGO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-25	Closed	-$21K	–	880
2022 Q2	$21K	Buy	+25	New	+$25.7K	﹤0.01%	823
2022 Q1	–	Sell	-81	Closed	-$146K	–	868
2021 Q4	$146K	Sell	81 -36	-31%	-$96.3K	0.01%	870
2021 Q3	$387K	Buy	117 +90	+333%	+$315K	0.02%	631
2021 Q2	$118K	Buy	+27	New	+$107K	0.01%	808

Other funds holding BNGO

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Mitsubishi UFJ Asset Management Tokyo, Japan $149B AUM 24.71% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return

Mutual Advisors's BNGO Position: Q3 2022 in Review

Mutual Advisors sold out of Bionano Genomics (BNGO) in Q3 2022, closing a stake of 25 shares — an estimated $21K sold.

Mutual Advisors first reported a position in BNGO in Q2 2021 and held it in 4 quarters. The position peaked at $387K in Q3 2021. 140 funds tracked by Wall St. Rank hold BNGO as of Q3 2022.

Mutual Advisors reported no remaining Bionano Genomics position as of Q3 2022 after selling out during the quarter.
Mutual Advisors sold 25 Bionano Genomics shares in Q3 2022, an estimated $21K.
Mutual Advisors first reported a position in Bionano Genomics in Q2 2021 and held it in 4 quarters.
Mutual Advisors's Bionano Genomics position peaked at $387K in Q3 2021.
140 funds tracked by Wall St. Rank held Bionano Genomics as of Q3 2022.

Based on Mutual Advisors's 13F filing for Q3 2022, filed 3 Nov 2022.